Hugel reports record first-half earnings driven by strong botulinum toxin growth
Hugel Oyj announced significant year-on-year increases in net sales, operating profit, and net income for the first half of 2026. The company's botulinum toxin products were a key driver of this growth.
Hugel Oyj has reported record financial results for the first half of 2026. Net sales increased by 27.2%, operating profit by 8.4%, and net income by 23.5% compared to the same period last year.
The strong performance was primarily attributed to robust growth in sales of its botulinum toxin products. The company has made strategic investments aimed at supporting long-term expansion, with the recent rollout of direct sales operations in the U.S. being a notable factor.
Hugel experienced balanced growth across its markets, with both medical aesthetic and cosmetic product segments contributing to the overall increase. The company anticipates this positive trend to continue in the foreseeable future.